Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-104IAR single-dose in knee osteoarthritis (Phase 2, randomized, double-blind, vehicle-controlled)
2021-000859-39Phase 2Completed
- Sponsor
- Eupraxia Pharmaceuticals Inc.
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluticasone propionate in knee osteoarthritis (OA) (2 arms), sponsored by Eupraxia Pharmaceuticals Inc. Primary endpoint: Primary: WOMAC Pain change from baseline at Week 12. Started Jun 2021; status: completed.
02
Drugs
fluticasone propionate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2021-000859-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000859-39.